Dear IH CYDY Board, I am upwithstock on Subreddit LT and

New Post Public Reply Private Reply Replies (2) Message Board
MLAB
1,495
Dear IH CYDY Board,
I am upwithstock on Subreddit LT and Livimmune
I have not posted here before, mainly because for me it has not been a user friendly experience. But occasionally I come here to read mainly ohm20; but I scan thru other posts from time to time and happen to see some posts that don't really seem to know the FDA process but comment on like they do. Plus, they don't seem to understand what has to be in place if you submit a BLA.

Any pharma company that submits a BLA, especially their first one (CYDY?), can be audited before the BLA is fully accepted or right after to see if the company is in FULL compliance with all things FDA. So what does that really mean? There are BOAT LOADS of quality documents that need to be in place for the drug, the CMC, the surveillance of trials and if approved a surveillance program for tracking complaints, adverse events and other possible quality issues. Like sterility, packaging, shipping container issues that could contaminate to product on the inside. All formulary documentation and I am not exaggerating when I say this but there is a ton more quality systems stuff that would blow your mind. Not even the safety data and trial data.

Why is this knowledge important? People don't seem to understand WHY, Cyrus pulled the HIV BLA back. The third party consultants that were hired and they were ex-FDA reviewers basically said if CYDY would submit a BLA, CYDY would not survive the AUDIT the FDA would surely do, because it would have been our first BLA submnission. Those generally get audited to make sure that all of the stuff I mentioned above and all of the other stuff I have not mentioned are in place and up to date. NP may of had 10% of this in place thanks to Nite Ray and the CMC data.
Because the audit team clearly saw nothing else was even close, they recommend to Cyrus to pull the HIV bLa submission. SMART MOVE.

But the third party auditors were not done working on all of the Amarex crap. Long story short, the auditors were able to validate the RAW DATA. This is the data that is cloected by clinicians that interface with the patients collect and eventually put into the electronic files. The CRO does not do that. They takle the electronic data and then basically agregate it and then they are supposed to put it the correct format. They are also supposed to follow strict surveillance protocols and other things. Amarex obviously failed all that. But, the data and the safety was intact. That is why Cyrus changed course and started talking more about HIV and HIV was mentioned more and more in SEC filings which I reference a TON in my posts. IMO and other familiar with BLA filings that the majority of the documents and other documents CYDY was working on are for passing a BLA submission audit. We HAVE NO DOUBTS ABOUT THAT. The clinical hold will be lifted and we feel based on experience that a BLA resubmission will happen at a minimum.

Regarding PIVOTAL TRIALS. geez... just look it up. The FDA and the sponsor in this case CYDY have reported that the HIV - MDR phase 2b/3 trial is a PIVOTAL TRIAL.Its in the 10K!! Meaning that the results would be submitted with the BLA submission and that trials data would be used to vote and yes or no at the PDUFA review. SO everything technically was achieved in the PIVOTAL TRIAL accept the freaking CRO screwed us.

Therefore, with all of the recent discoberies of the shennigans that the FDA pulled with Suzanne Strayhorn and Amarex screwing us. The FDA had the UNUSUAL PDUFA-likje panel meeting. The only thing different about that meeting is: it was not public (PDUFA meetings are public) and there was not vote of yes or no...as far as we know. IMO, the FDA has a credibility issue and also understands that CYDY got screwed from multiple directions. Since there seems to be unprecedent FDA failings and they don't want this to go public. it already has, but they have been help Cyrus with all of the other things CYDY needs to have in place to pass a BLA audit.

This has attributed to the length of time it has taken to get to this point and iMO CYDY had to be silent about a lot of this shit.

My apologies for Capital letters but I have been misquoted too many times. I wish all the longs the very best. Most importantly I hope and pray that CYDY can move forward and get LL into physicians hands to start treating patients in need. I thank you all for your patience with this long post.
Happy Thanksgiving from MLAB/Upwithstock

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Everest Group Faces Shaky Ground in Securities Fraud Suit

Updated Category News Views 128

Investors Take Aim at Everest Group's Alleged Missteps Looks like Everest Group, Ltd. (NYSE: EG) has found itself knee-deep in legal quicksand. There's a class-action lawsuit afoot, spearheaded by the folks at Schall, Brown & Schwartz LLP. They're putting forward claims that Everest, a player in the securities exchange, was painting a misleading picture when it came to...

Continue Reading
Doppel's Strategic Expansion: Adding PropRise Innovators

Updated Category News Views 62

Doppel Boosts Its Team with PropRise Founders The market doesn’t lie: when a company's on a roll, you watch it closely. Doppel's latest move is a serious signal. They've snagged PropRise, a sprightly Y Combinator graduate, and landed its founders, Jean-Michael Diei and Matthew Krager, right into their engineering fold. These guys aren't greenhorns—cutting their teeth...

Continue Reading
Johnsonville's Election Effort: Sausage for Dinner Gains Momentum

Updated Category News Views 88

Sausage Politics: A Tasty New Agenda Well, ain't that something? A sausage campaign running parallel to the midterms wasn't exactly on my bingo card. But here we are, America, dealing with a 'Sausage Tsunami.' This cheeky strategy from Johnsonville sure packs a punch, leveraging electoral fatigue to put sausage right where they want it: on your dinner plate. The Campaign...

Continue Reading
Silvercorp Updates El Domo Budget Amid Challenges

Updated Category News Views 141

Budget Pains for Silvercorp's El Domo Project Folks, if you thought navigating the stock market was a minefield, try mining these days. Silvercorp Metals Inc. had to bump up its budget for the El Domo project in Ecuador—again. This time by $14.6 million. What's causing this fiscal heartache? Everything from rising diesel prices thanks to Ecuador playing games with...

Continue Reading
Historic Surge: Women Veterans Join 120th Congress

Updated Category News Views 107

The Winds of Change Are Blowing Through Washington It looks like the face of Congress is getting a combat-ready makeover with the latest election results. Veterans are stepping up to the plate, claiming at least 79 seats in the 120th Congress, with a historic presence of women veterans making waves. Yeah, we're talking about 11 women veterans hitting the halls of power,...

Continue Reading
Life with PAH: A Journey of Awareness and Hope

Updated Category News Views 230

Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...

Continue Reading
The Braff Group's 400th Health Care M&A Milestone

Updated Category News Views 31

No one just stumbles into 400 successful deals without a whole lot of grit, especially in the gnarly jungle of health care services mergers and acquisitions. The Braff Group, a stalwart in this arena since 1998, has just hit this remarkable milestone. If you ask me, this isn't just a number—it's a testament to the blood, sweat, and relentless dedication poured into...

Continue Reading
Citius Unveils Promising LYMPHIR Data at EORTC Conference

Updated Category News Views 77

A Closer Look at LYMPHIR's Impact on CTCL Patients Well, here's a whiff of genuine hope for folks grappling with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Coming out of New Jersey, Citius Oncology has dished out some pretty promising news, fresh from the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group's annual...

Continue Reading
Webull Corp Caught in Legal Storm; Investors Take Note

Updated Category News Views 87

A Legal Storm Brewing It's like walking into a saloon, expecting a smooth drink, only to find a bar fight breaking out in front of you. That's the scene with Webull Corporation (NASDAQ: BULL) right now. This time, they ain't just shooting the breeze; they're in the line of legal fire. SBS Law, a heavyweight in shareholder rights, is rallying the troops for a class action...

Continue Reading
NACCO Navigates Strong 2026 Q3, Faces Solar Cost Hurdles

Updated Category News Views 34

Rolling With NACCO's Financial Punches Well, folks, when it rains, it pours—numbers that is. NACCO Industries just laid out their Q3 results for all to gawk at, and it's a mixed bag of triumphs and tussles. You got a gross profit of $11.8 million, a sweet 18% jump on the same quarter last year. Now, you're talking about revenue muscle, and there it is. Income before...

Continue Reading

Top 5 Most Recently Viewed Articles

Alex Bastian Named VP of Commercial Strategy at Memo Therapeutics

Updated Category News Views 282

Alex Bastian Appointed as VP of Commercial Strategy at Memo Therapeutics AG Memo Therapeutics AG (or “MTx”), a late-stage biotech firm committed to transforming unique human immune responses into effective treatments for viral infections and cancer, has announced the appointment of Alex Bastian as its new VP of Commercial Strategy. Expertise in the Biotech Industry...

Continue Reading
Understanding Alliant Energy's Rising Short Interest Insights

Updated Category News Views 282

Alliant Energy's Rising Short Interest Alliant Energy's short percent of float has recently increased, reaching 9.49% since the last report. The energy provider has reported a total of 7.74 million shares sold short. This accounts for about 3.46% of its total available shares for trading, indicating an active trading environment. Understanding Short Interest Short...

Continue Reading
China's 2024 Fiscal Revenue: A Shift Towards Proactive Measures

Updated Category News Views 270

China's Fiscal Revenue Growth and Economic Challenges In recent reports, it's shown that China's fiscal revenue in 2024 has seen an increase of 1.3% year on year. This rate of growth is a significant decline from the 6.4% expansion recorded in 2023. The slowdown in revenue has raised concerns amid economic uncertainties. The Impact of the Property Market One of the...

Continue Reading
Troomi CEO Bill Brady Strengthens Commitment to Youth Mental Health

Updated Category News Views 542

Troomi CEO Bill Brady Strengthens Commitment to Youth Mental Health In a significant step forward for youth mental health advocacy, Bill Brady, the CEO of Troomi Wireless, has been appointed to the Board of Directors of Speak Our Minds, a nonprofit organization dedicated to combatting the youth mental health crisis. This collaboration aims to unite technology with a...

Continue Reading
Investigation of Investors' Claims Against Unisys Corporation

Updated Category News Views 467

Rosen Law Firm Investigates Claims for Unisys Corporation Investors Rosen Law Firm, a well-respected global investor rights organization, is currently conducting an investigation concerning potential securities claims on behalf of shareholders of Unisys Corporation (NYSE: UIS). This investigation arises from serious allegations suggesting that Unisys might have provided...

Continue Reading